Cell-based assays take place within a living cell. It is grouped into cell signaling assays, reporter gene assays, cell death assays, and cell proliferation assays. It is a preclinical development tool used in the pharmaceutical industry and research laboratories to reverse the increasing trend of costly late-stage drug failures and save investments. Cell-based assays lower the downstream cost and reduce animal models, which are used for toxicity and metabolism study and can be expensive and reason to drug failures at the late stage of preclinical testing. Also, animal models may not always replicate human metabolism, which can result in late-stage failure.
The global cell-based assays market size is growing at a significant CAGR during the forecast period, 2020-2027. The growing demand for cell-based assays is rising drug discovery activities and increasing R&D investments. Additionally, the increasing utilization of cell-based assays in the pharmaceutical& biotechnology industry and CROs will spur the global cell-based assays industry in the future periods. Furthermore, the growing public-private funding for cell-based assays and the easy research in the area of stem cell, cancer immunology, and immunogenicity is expected to witness remarkable growth of cell-based assays. The increasing clinical usage of cell-based assays in pharmacology, including cytotoxicity testing, development of novel small molecules, bio-therapeutic and cell-based therapies, are expected to propel the demand for cell-based assays over the coming years.
Moreover, the upsurge in demand for cell-based assays in pharmaceutical industries to overcome the expensive failure of last-stage drugs and failure of investigation of new drugs is positively impacting the market for cell-based assays in the healthcare industry. Furthermore, the rapidly enlarge customer base, rise in the extensive R&D activities at the academic and industrial level, and increasing scope of high-throughput screening formats are fueling the demand for cell-based assays in the healthcare market. The rising adoption of label-free cell-based assays with optical biosensors in drug discovery will bolster the growth of the global cell-based assays market share. The growing geriatric population and increasing healthcare awareness in the developing world propelling the maturation of the cell-based assays market across the globe.
A cell-based assay is used to manufacture novel drugs, which can effectively reduce the manufacturing cost and investigate basic cell biology and its relation to disease pathology. Due to huge advantages such as the possibility of automation, miniaturization, predictability, and multiplexing seem the most useful tool for the high demands of the early stages of the drug-discovery process. Improvements made in high content systems and technological developments have attracted various enterprises to the layout. However, the high cost of instruments may restrict the growth of the market. Moreover, the increasing adaptation of high throughput technology in life science research, drug discovery & development, environment monitoring, and biopharmaceutical production process.
Based on the product, the global cell-based assays market is segregated into consumables, instruments, services, and software. The consumables segment is further classified into reagents, microplates, probes & labels, assay kits, cell lines, etc. The Consumables segment is estimated to the highest growth over the analysis timeframe due to increasing cell-based assays in drug discovery and increasing biomedical research activities.
The instruments will grow significantly due to the rising adoption in the diagnostics field, analyze complex cellular functions, and measure proliferation, cell viability, cytotoxicity, and a reporter gene.
Based on the application, the global cell-based assays market is classified into drug discovery, basic research, ADME studies, predictive toxicology, etc. The drug discovery is to be the highest revenue share for cell-based assays during the forecast period. The segment’s growth is generally attributed to the growing use of the cell-based assays technology in the pharmaceutical & biotechnology industry to determine the biological activity (potency) of a drug product and to save the investment of late-stage drug failures.
The ADME studies will witness a lucrative growth rate in the estimated period due to the increasing demand for cytotoxicity testing and rising R&D investment by pharmaceutical companies.
Based on the end-user, the global cell-based assays market is segmented into pharmaceutical & biotechnology companies, academic and government research institutes, contract research organizations (CRO), other end users. The pharmaceuticals & biotechnology segment will dominate the global cell-based assays market by 2027 due to the increasing use of cell-based assays in a clinical trial setting and novel drug development.
The CMOS accounted for the largest share of the cell-based assays market in 2019 on account of providing more early drug development services and increasing the use of cell-based assays for research activities.
The global cell-based assays market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa by geography. North America is estimated to project considerable growth over 2020-2026. It is due to leading industry players offering innovative products, Increasing awareness towards cell-based assays for drug discovery, and increasing healthcare expenditure.
The Asia Pacific will produce a prominent share of the cell-based assays market by 2027. Due to the rise in cell-based assays applications, we are continually improving the healthcare framework in the region and mounting health care amenities in emerging countries such as India and China.
Companies such as Envision TEC, Stratasys Inc., Materialise NV, 3D Systems Software, Bio-Rad Laboratories, Organovo, SOLS, Simbionix, Metamason, RegenHU Ltd., Youbionic, Bio3D Technologies Pte Ltd, 3D Matters Pte Ltd., 3D Systems Corporation (3DS), Ekso Bionics, Roche Pharmaceuticals, Renishaw plc., Robohand, Delcam India, Worrell, mobileOCT, Arkham, Rainbow Biosciences, ALD Vacuum Technologies, and 3T RPD Ltd are the key players in the global cell-based assays market.
By Product
By Application
By End-User
By Region
CT
Analyst support
After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.
Customer satisfaction
According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.
Inimitable expertise
Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.
Assured quality
We have created a systematic way to determine standards and satisfy your expectations.
Instant delivery
Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.
Privacy policy
We understand the inkling of your privacy, we will never misuse your email address.
Custom research service
We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.
Quality & accuracy
We provide you with the accurate quality of the customized study of an exclusive report according to your research need.
Data visualization
As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.
Information security
We truly respect your privacy and promise to keep your personal and confidential information safe and secure.